While one could argue that we should give the release a pass given the early stage of the research, the drugs discussed are commercially available and it would have been easy to provide cost information. The release provides insufficient detail regarding what occurred in this study and the outcomes that were reported. The release states that “both drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs.” But how many animals were studied, and how many of them regained use of their limbs? Was there total resolution of symptoms or only partial resolution, and how was this measured? The release never quantifies these results. Dr. Tesar provides a cautionary note related to the potential harms of this approach; “Off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.” Given the stage of research, we think this is sufficient to rate this criterion as satisfactory Our major concern with the description of evidence is that the release waits too long to inform readers that these results were obtained in petri dishes and mice. We have to read more than halfway through the release to learn of this crucial caveat. We also had concerns about the headline as noted above in the Review Summary section. To its credit, the news release does provide an important cautionary statement: “…more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials.” But this statement, coming late in the release, is too little to counterbalance the enthusiasm generated earlier in the release based on an incomplete and possibly misleading description of the evidence. No disease mongering is evident. We are told up front that the study was funded by a division within the National Institutes of Health, and there is no apparent conflict of interest according to the paper. The news release earns a Satisfactory rating by speaking to the current treatments that are available: “Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability.” To earn extra credit here, the release could have provided a comment about other research into improving myelin production. This includes ongoing clinical trials being conducted by Biogen and others targeting myelin production in MS. The story makes it clear that the two drugs highlighted (clobetasol and miconazole) are available and adds the important precatuionary note, “…are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.” This is indeed first of its kind research and that is appropriately noted in the news release. With the possible exception of the headline — an issue we’ve already addressed elsewhere in this review — no hyperbole is evident.
Drugs that activate brain stem cells may reverse multiple sclerosis